A new type of depression drug from Neumora has failed the first of three Phase 3 trials, marking a gloomy beginning to 2025 for the brain disease biotech

Navacaprant performed almost the exact same as placebo on the primary endpoint. J&J is testing a similar type of KOR antagonist dubbed aticaprant